参考文献/References:
[1] Pulliam JRC,van Schalkwyk C,Govender N,et al.Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa[J].Science,2022,376(6593):eabn4947.
[2] Huang C,Wang Y,Li X,et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China[J].Lancet,2020,395(10223):497-506.
[3] Wu Z,Mcgoogan JM.Characteristics of and important lessons from the coronavirus disease 2019(COVID-19)outbreak in China:Summary of a report of 72314 cases from the chinese center for disease control and prevention[J].JAMA,2020,323(13):1239-1242.
[4] 黄 明,杨丰文,郑文科,等.中医药治疗新型冠状病毒肺炎方舱医院的建立与成效[J].天津中医药,2022,39(6):684-687.
[5] Valencia DN.Brief review on COVID-19:The 2020 pandemic caused by SARS-CoV-2[J].Cureus,2020,12(3):e7386.
[6] 周 娟,李 丹,龙云铸.新型冠状病毒(2019-nCoV)相关研究进展[J].中国感染控制杂志,2020,19(3):288-292.
[7] 贾 明,王 虹,宋春利,等.新型冠状病毒肺炎文献整理及研究概述[J].陕西医学杂志,2020,49(3):259-266.
[8] Rio CD,Malani PN,Omer SB.Confronting the delta variant of SARS-CoV-2,summer 2021[J].JAMA,2021,326(11):1001-1002.
[9] Bernal JL,Andrews N,Gower C,et al.Effectiveness of Covid-19 vaccines against the B.1.617.2(delta)variant[J].N Engl J Med,2021,383(27):2603-2615.
[10] Li XN,Huang Y,Wang W,et al.Effectiveness of inactivated SARS-CoV-2 vaccines against the delta variant infection in Guangzhou:A test-negative case-control real-world study[J].Emerg Microbes Infect,2021,10(1):1751-1759.
[11] 周启明,陈 磊,王惟信,等.新型冠状病毒疫苗接种与疫情进展[J].微生物与感染,2021,16(6):431-438.
[12] Chen N,Zhou M,Dong X,et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,China:A descriptive study[J].Lancet,2020,395(10223):507-513.
[13] Li B,Yang J,Zhao F,et al.Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China[J].Clin Res Cardiol,2020,109(5):531-538.
[14] Lippi G,Wong J,Henry BM.Hypertension and its severity or mortality in coronavirus disease 2019(COVID-19):A pooled analysis[J].Pol Arch Intern Med,2020,130(1987):304-309.
[15] Wang D,Hu B,Hu C,et al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan,China[J].JAMA,2020,323(11):1061-1069.
[16] Wan Y,Shang J,Graham R,et al.Receptor recognition by novel coronavirus from Wuhan:An analysis based on decade-long structural studies of SARS[J].J Virol,2020,94(7):e00127.
[17] Li XC,Zhang J,Zhuo JL.The vasoprotective axes of the renin-angiotensin system:Physiological relevance and therapeutic implications in cardiovascular,hypertensive and kidney diseases[J].Pharmacol Res,2017,125(Pt A):21-38.
[18] Gavriilaki E,Anyfanti P,Gavriilaki M,et al.Endothelial dysfunction in COVID-19:Lessons learned from coronaviruses[J].Curr Hypertens Rep,2020,22(9):63.
[19] 王 霜,王贵佐,唐 甜,等.新型冠状病毒肺炎发病机制及药物治疗研究进展[J].陕西医学杂志,2021,50(5):638-641.
[20] 王芬芬,马卫国,殷小红,等.新冠肺炎合并糖尿病研究现状及对血糖影响因素的探讨[J].基层医学论坛,2021,25(28):4022-4025.
相似文献/References:
[1]郑宏波,于 芳△,王一龙,等.陕西咸阳地区新型冠状病毒肺炎流行病学研究[J].陕西医学杂志,2020,49(4):387.
ZHENG Hongbo,YU Fang,WANG Yilong,et al.Epidemiological investigation of corona virus disease 2019 in Xianyang area[J].,2020,49(12):387.
[2]王 霜,王贵佐,唐 甜,等.新型冠状病毒肺炎发病机制及药物治疗研究进展[J].陕西医学杂志,2021,50(5):638.[doi:DOI:10.3969/j.issn.1000-7377.2021.05.031]